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Ethosomes are the ethanolic phospholipid vesicles which are used mainly for transdermal 
delivery of drugs. Ethosomes have higher penetration rate through the skin as compared to 
liposomes hence these can be used widely in place of liposomes. The increased permeation 
of ethosomes is probably due to its ethanolic content. Ethanol increases the cell membrane 
lipid fluidity which results in increased skin penetrability of the ethosomes. Transdermal 
administration of drugs is generally limited by the barrier function of the skin. Vesicular 
systems are one of the most controversial methods for transdermal delivery of active 
substances. The interest in designing transdermal delivery systems was relaunched after the 
discovery of elastic vesicles: transferosomes and liposomes. This article reviews various 
aspect of ethosomes including their preparation, characterization, potential advantages and 
their applications in drug delivery. Because of their unique structure, ethosomes are able to 
encapsulate and deliver through the skin highly lipophilic molecules such as cannabinoids, 
testosterone, andminoxidil, as well as cationic drugs such as propranolol, trihexyphenidil, 
Cyclosporine A, insulin, salbutamol etc.. Ethosomes provides a number of important benefits 
including improving the drug’s efficacy, enhancing patient compliance and comfort and 
reducing the total cost of treatment. 
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Introduction 
The skin covers a total surface area of approximately 
1.8m2and provides the contact between the human body and 
the external environment. Dermal drug delivery is the topical 
application of drugs to the skin in the treatment of skin 
diseases and other inflammatory conditions. This has the 
advantage that high concentrations of drugs can be localized 
at the site of action, reducing the systemic side effects. 
Transdermal drug delivery uses the skin as an alternative route 
for the delivery of systemically acting drugs. Ethosomes are 
novel carrier system used for delivery of drugs having low 
penetration through the biological membrane mainly skin. 
Ethosomes are the slight modification of well-established drug 
carrier liposome Figure1. Ethosomes are lipid vesicles 
containing phospholipids, alcohol (ethanol and isopropyl 
alcohol) in relatively high concentration and water [1]. 
Transdermal drug delivery offers many advantages as 
compared to traditional drug delivery systems, including oral 
and parenteral drug delivery system. Advantages claimed are 
increased patient acceptability (noninvasiveness), avoidance of 
gastrointestinal disturbances and first pass metabolism of the 
drug[2].The traditional transdermal drug delivery systems 
involve a patch, in which the drug permeates through various 
layers of skin, via a passive diffusion pathway. However, this 
limits the basic potential of these systems, as stratum corneum 
is the most formidable barrier to the passage of most of the 
drugs, except for highly lipophilic, low molecular weight drugs 
[3]. To overcome the stratum corneum barrier, various 
mechanisms have been investigated, including use of chemical 
or physical enhancers, such as iontophoresis, sonophoresis, 
etc. Liposomes, niosomes, transferosomes and ethosomes 
also have the potential of overcoming the skin barrier and have 
been reported to enhance permeability of drug through the 
stratum corneum barrier. [4].                     
The vesicles have been well known for their importance in 
cellular communication and particle transportation for many 
years. Researchers have understood the properties of vesicles 
structure for use in better drug delivery within their cavities, 
which would to tag the vesicle for cell specificity. One of the 
major advances in vesicle research was the finding a vesicle 
derivatives, known as an Ethosomes [5]. Ethosomes are the 
ethanolic phospholipid vesicles which are used mainly for 
transdermal delivery of drugs. Ethosomes have higher 
penetration rate through the skin as compared to liposomes 
hence these can be used widely in place of liposomes. The 
increased permeation of ethosomes is probably due to its 
ethanolic content [6]. Ethanol increases the cell membrane 
lipid fluidity which results in increased skin penetrability of the 
ethosomes. These ethosomes permeates inside the skin and 




fuse with cell membrane lipids and release the drug. Hot and 
cold methods are used for formulation of ethosomes 
[7]. Ciclopiroxolamine is an antifungal drug for treatment of 
cutaneous candidiasis infections. The goal of the current 
investigation is to evaluate the transdermal potential of novel 
vesicular carrier, ethosomes, bearing ciclopiroxolamine an 
antifungal having limited transdermal permeation. Ciclopirox 
olamine loaded ethosomes were prepared, optimized and 
characterized for vesicular shape and surface morphology, 
vesicular size, size distribution, entrapment efficiency, vesicles 













Fig 1:-proposed diagram of ethosomes. 
 
Advantages of Ethosomal Drug Delivery 
1. Ethosomes are enhanced permeation of drug through skin 
for transdermal and dermal delivery. 
2. Ethosomes are platform for the delivery of large and diverse 
group of drugs (peptides, protein molecules)  
3. Ethosome composition is safe and the components are 
approved for pharmaceutical and cosmetic use. 
4. Simple method for drug delivery in comparison to 
Iontophoresis and Phonophoresis and other complicated 
methods. 
5. It contains non‐toxic raw material in formulation. 
6. High patient compliance‐The ethosomal drug is 
administrated in semisolid form (gel or cream) hence 
producing high patient compliance. 
7. The Ethosomal system is passive, non‐invasive and is 
available for immediate commercialization. 
8. Low risk profile- The technology has no large-scale drug 
development risk since the toxicological profiles of the 
ethosomal components are well documented in the scientific 
literature. 
 
Mechanism of Drug Penetration 
The enhanced delivery of actives using ethosomes over 
liposomes can be ascribed to an interaction between 
ethosomes and skin lipids. A possible mechanism for this 
interaction has been proposed. It is thought that the first part of 
the mechanism is due to the ‘ethanol effect whereby 
intercalation of the ethanol into intercellular lipids increasing 
lipid fluidity and decreases the density of the lipid multilayer 
[10,11]. This is followed by the ‘ethosome effect’, which 
includes inter lipid penetration and permeation by the opening 
of new pathways due to the malleability and fusion of 
ethosomes with skin lipids, resulting in the release of the drug 






















Fig 2:- Mechanism of action of ethosomes 
 
The main advantage of ethosomes over liposomes is the 
increased permeation of the drug. The mechanism of the drug 
absorption from ethosomes is not clear. The drug absorption 
probably occurs in following two phases: 




1. Ethanol effect 
2. Ethosomes effect 
 Ethanol effect 
Ethanol acts as a penetration enhancer through the skin. 
The mechanism of its penetration enhancing effect is well 
known. Ethanol penetrates into intercellular lipids and 
increases the fluidity of cell membrane lipids and decrease the 
density of lipid multilayer of cell membrane. 
 Ethosomes effect 
Increased cell membrane lipid fluidity caused by the 
ethanol of ethosomes results increased skin permeability. So 
the ethosomes permeates very easily inside the deep skin 
layers, where it got fused with skin lipids and releases the 
drugs into deep layer of skin. 
 
Method of Preparation 
There are two methods which can be used for the 
formulation and preparation of ethosomes. Both methods are 
very simple and convenient and not any sophisticated 
instrument use or any complicated process. Ethosomes can be 
made by following two methods 
Hot method: - In this method phospholipid disperse in 
water by heating in a water bath at 400 ⁰C until a colloidal 
solution is obtained. In a separate vessel properly mix ethanol 
and propylene glycol and heat up to 400c. Add the organic 
phase into the aqueous phase. Dissolve the drug in water or 
ethanol depending on its solubility [12,13]. The vesicle size of 
ethosomal can be decreased to the extent of our need using 
probe sonication or extrusion method. 
Cold method: - This is the most common and widely used 
method for the ethosomal preparation. Dissolve phospholipid, 
drug and lipid materials in ethanol in a vessel at room 
temperature with vigorous stirring. Add propylene glycol during 
stirring. Heat the mixture upto 300 ⁰C in a water bath. Heat the 
water up to 300ºC in a separate vessel and add to the mixture 
and then stir it for 5 min in a covered vessel. The vesicle size 
of ethosomal formulation can be decreased to desire extend 
using sonication 6 or extrusion 13 method [14,15]. Finally, the 
formulation should be properly stored under refrigeration. 
 
Various Methods for Characterization of Ethosomes 
1. Vesicle shape: - Ethosomes can be easily visualized by 
using transmission electron microscopy (TEM) and by 
scanning electron microscopy (SEM) [16]. 
2. Vesicle size and zeta potential:- Particle size of the 
ethosomes can be determined by dynamic light scattering 
(DLS) and photon correlation spectroscopy (PCS). Zeta 
potential of the formulation can be measured by Zeta meter 
[17]. 
3. Transition temperature: - The transition temperature of the 
vesicular lipid systems can be determined by using 
differential scanning calorimetry (DSC) [18]. 
4. Drug entrapment: - The entrapment efficiency of ethosomes 
can be measured by the ultracentrifugation technique [19]. 
5. Drug content: - Drug content of the ethosomes can be 
determined using UV spectrophotometer. This can also be 
quantified by a modified high performance liquid 
chromatographic method [20]. 
6. Surface tension measurement: - The surface tension activity 
of drug in aqueous solution can be measured by the ring 
method in a Du Nouy ring tensiometer. 
7. Stability studies: - The stability of vesicles can be 
determined by assessing the size and structure of the 
vesicles over time. Mean size is measured by DLS and 
structure changes are observed by TEM. 
8. Skin permeation studies: - The ability of the ethosomal 
preparation to penetrate into the skin layers can be 
determined by using confocal laser scanning microscopy 
(CLSM).Table 1 shows Characterization of ethosomes. [21]
 
 
Table 1: Characterisation of ethosomes. 
s.no 
 
Parameter  Importance Method 
1 
 
Size and shape  Determine skin penetration SEM, TEM, DLS 
2 
 
Zeta potential  Stability of vesicles Zeta Meter 
3 
 
Entrapment efficiency  Suitability of method Ultracentrifugation 
4 
 
Drug content  Important in deciding the amount of 
vesicle preparation 




Stability studies  To determine the shelf life of vesicle 
formulation 
SEM, TEM, HPLC 
6 
 
Invitro dissolution  Determine the drug release rate from 
vesicle 
Franz diffusion cell 





Various vesicular structures as skin delivery systems 
In the last years, the vesicular systems have been 
promoted as a mean of sustained or controlled release of 
drugs, because of their certain advantages, e.g. lack of toxicity, 
biodegradation, capacity of encapsulating both hydrophilic and 
lipophilic molecules, capacity of prolonging the existence of the 
drug in the systemic circulation by encapsulation in vesicular 
structures, capacity of targeting the organs and tissues, 




capacity of reducing the drug toxicity and increasing its 
bioavailability. Vesicles are water-filled colloidal particles. The 
walls of these capsules consist of amphiphilic molecules (lipids 
and surfactants) in a bilayer conformation. In an excess of 
water these amphiphilic molecules can form one (unilamellar 
vesicles) or more (multilamellar vesicles) concentric bilayers. 
Hydrophilic drugs can be entrapped into the internal aqueous 
compartment, whereas amphiphilic, lipophilic and charged 
hydrophilic drugs can be associated with the vesicle bilayer by 
hydrophobic and/or electrostatic interactions [22, 23]. 
Most commonly, the vesicles are composed of 
phospholipids or nonionic surfactants. The reason for using 
vesicles in transdermal drug delivery is based on the fact that 
they act as drug carriers to deliver entrapped drug molecules 
across the skin, as well as penetration enhancers because of 
their composition. In addition, these vesicles serve as a depot 
for the sustained release of active compounds in the case of 
topical formulations, as well as rate-limiting membrane barrier 
for the modulation of systemic absorption in the case of 
transdermal formulations [24]. 
Liposomal formulations can be classified in two 
categories: rigid vesicles – liposomes and niosomes – and 
elastic or ultradeformable vesicles – transferosomes and 
ethosomes. 
Niosomes: -Niosomes are vesicles composed of nonionic 
surfactants. The niosomes have been mainly studied because 
of their advantages compared with the liposomes: they are 
quite stable structures and require no special conditions for 
preparation and storage, they have no purity problems and the 
manufacturing costs are low. Unfortunately, the performed 
studies showed that, like liposomes, niosomes are not suitable 
for transdermal delivery, because they cannot reach the 
deeper layers of the skin, being trapped in the superior layers 
of stratum corneum. To overcomethis problem, the carried out 
researches introduced a novel generation of vesicular elastic 
systems: transferosomes (ultradeformable vesicles consisting 
of phospha- tidylcholine and an edge activator) and ethosomes 
(ultradeformable vesicles with high alcohol content) [25]. 
Transferosomes: -Transferosomes are a special type of 
liposomes, consisting of phosphatidylcholine and an edge 
activator. The concept of transferosomes was introduced in 
1992 by Cevc and coworkers. These vesicular transferosomes 
are several orders of magnitude more elastic than the standard 
liposomes and thus well suited for the skin penetration [26]. 
Ethosomes 
Ethosomes are deformable liposomes with high alcohol 
content (up to 45%). It is proposed that the alcohol fluidizes the 
ethosomal lipids and stratum corneum bilayer lipids thus 
allowing the soft, malleable ethosomes to penetrate. They 
have been introduced for the first time by Touitou in 1996. The 
ethanol from ethosomes composition plays the same role as 
the surfactant from the transferosomes, namely disorganizing 
the lipid bilayer, conferring a ten times higher deformability to 
the particles [27]. 
 
Evaluation of ethosomes 
1. Visualization by scanning electron microscopy (SEM):- 
The size and shape of the vesicles were observed in the 
scanning electron microscopy. One drop of ethosomal 
suspension (F16) was mounted on a clear glass stub. It was 
then air dried and gold coated using sodium auro thiomalate to 
visualize under scanning electron microscope at 10,000 
magnifications [28]. 
2. Determination of entrapment efficiency: - Entrapment 
efficiency of diclofenac potassium ethosomal vesicles was 
determined by centrifugation method. The vesicles were 
separated in a high speed cooling centrifuge at 20,000 rpm for 
90 minutes in the temperature maintained at 4ºC. The 
sediment and supernatant liquids were separated; amount of 
drug in the sediment was determined by lysing the vesicles 
using methanol. From this, the entrapment efficiency was 
determined by the following equation [29], 
Entrapment efficiency = DE ⁄ DT x 100 Where, 
DE ― Amount of drug in the ethosomal sediment 
DT― Theoretical amount of drug used to prepare the 
formulation 
         (equal to amount of drug in supernatant liquid and in 
the sediment). 
3.Vesicular size and size distribution: - Dynamic light 
scattering technique was used to determine the vesicular size 
and size distribution. One drop of ethosomal formulation was 
diluted to 10ml with hydroethanolic mixture used in the 
formulation and the measurements were taken. The size 
distribution of the liposome formulation was also determined 
after diluted with distilled water [30]. 
4. Comparison of in vitro skin permeation of drug forms 
various formulations: -Invitro skin permeation of diclofenac 
potassium in ethosomes, liposomes, hydroethanolic solution 
(1%w/v) and in phosphate buffer saline pH 7.4 (1%w/v) were 
studied using Franz diffusion cell with an effective permeation 
area of 2.54cm2. The ethosomal formulation was selected for 
the in vitro skin permeation on the basis of high entrapment 
efficiency and smaller vesicular size. Rats (male albino) 6 to 8 
weeks old, weighing 120 to 150g were sacrificed for abdominal 
skin. After removing the hair, the abdominal skin was 
separated from the underlying connective tissue with scalpel. 
The excised skin was placed on aluminum foil and the dermal 
side of the skin was gently teared off for any adhering fat 
and/or subcutaneous tissue. The skin was checked carefully to 
ensure the skin samples are free from any surface irregularity 
such as fine holes or crevices in the portion that is used for 
transdermal permeation studies. The in vitro study was 
approved by the institutional ethical committee. The skin was 
mounted between donor and receptor compartment with the 
stratum corneum side facing upward into the donor 
compartment. Phosphate buffer saline pH 7.4 was taken in the 
receptor compartment. The formulation was applied on the skin 
in donor compartment which was then covered with aluminum 
foil to avoid any evaporation process. Samples were withdrawn 
at predetermined time intervals over 12 hours, and suitably 
diluted with phosphate buffer saline pH 7.4 to analyze the drug 
content in UV‐Visible spectrophotometer at 276nm using 
phosphate buffer saline pH 7.4 as blank. The receptor medium 
was immediately replenished with equal volume of fresh 
medium to maintain the sink conditions throughout the 
experiment. The percentage of drug release was plotted 
against time to find the drug release pattern [31]. 
5. Skin retention studies: -The amount of diclofenac 
potassium retained in the skin was determined at the end of 
the 12 hours Invitro permeation studies. The formulation 




remain in the invitro permeation experiment was removed by 
washing with distilled water. The receptor content was 
replaced by 50% v/v ethanol and kept for further 12 hours with 
stirring and the drug content was estimated 
spectrophotometrically at 276nm. This receiver solution 
diffused through the skin, disrupting any liposome and 
ethosome structure and extracting deposited drug from the 
skin. 
6.FTIR studies: - Stability studies were carried out by 
storing the ethosomal formulations at two different 
temperatures 4ºC and 25±2ºC. The drug content was 
estimated for every 15 days to identify any change in the 
entrapment efficiency of ethosomal formulation. 
7. Stability studies: - Stability studies were carried out by 
storing the ethosomal formulations at two different 
temperatures 4ºC and 25±2ºC. The drug content was 
estimated for every 15 days to identify any change in the 
entrapment efficiency of ethosomal formulation. 
 
Therapeutic Application of Ethosomes 
Touitou et al. experimentally tested the effect of an 
ethosomal insulin formulation that was applied to the skin on 
blood glucose level. The ethosomal formulation caused much 
as a 60% decrease in blood glucose levels in both normal and 
diabetic rats and kept the level constant for at least 8 hours 
[32] 
Ethosomes as a carrier of various drug molecules has 
been listed below table 2.Horwitz et al. reported that a 5 % 
acyclovir ethosomal preparation compared to the 5 % acyclovir 
cream showed significant improvements in treatment of 
herpetic infections [33]. 
Esposito et al. investigated basic properties and the in 
vitrorelease rate kinetics of azelaic acid, alternatively 
vehiculated in different phospholipid-based vesicles such as 
ethosomes or liposomes. Diffusion of azelaic acid from 
ethosomal or liposomal dispersions and from ethosomes and 
liposomes incorporated in a viscous gel was investigated by a 
Franz cell assembled with synthetic membranes. The release 
rate was more rapid from ethosomal systems than from 
liposomal systems [34]. 
 




Acyclovir   Treatment of Herpetic infection Improved drug delivery 
Zidovudine  Treatment of AIDS   Improved transdermal flux 
TrihexyphenidylHCl  
 
Treatment of Parkinsonian syndrome   Increased drug entrapment efficiency, reduced side effect 
& constant systemic levels 
 
Erythromycin  
Efficient healing of S. aureus -induced deep 
dermal infections  
Improved drug penetration and systemic effect. 
Insulin   Treatment of Diabetes   Improved therapeutic efficacy of drug 
Testosterone   Treatment of male hypogonodism Enhance skin permeation 
Bacitracin    Treatment of dermal infections Reduced drug toxicity  
Minodixil   Hair growth promotion effect Higher skin retention 
 
Conclusion 
Ethosomal carrier opens new challenges and 
opportunities for the development of novel improved 
therapies.Ethosomes are soft, malleable vesicles and potential 
carrier for transportation of drugs. Ethosomes are 
characterized by simplicity in their preparation, safety and 
efficacy and can be tailored for enhanced skin permeation of 
active drugs. Ethosomes have been found to be much more 
efficient at delivering drug to the skin, than either liposomes or 
hydroalcoholic solution.It can be easily concluded that 
ethosomes can provide better skin permeation than liposomes. 
The main limiting factor of transdermal drug delivery system 
i.e. epidermal barrier can be overcome by ethosomes to 
significant extent. Application of ethosomes provides the 
advantages such as improved permeation through skin and 
targeting to deeper skin layers for various skin diseases. 
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